FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387474477> ?p ?o ?g. }

• W4387474477 endingPage "103118" @default.
• W4387474477 startingPage "103118" @default.
• W4387474477 abstract "The role of autoreactive T cells on the course of Coronavirus disease-19 (COVID-19) remains elusive. Type II pneumocytes represent the main target cells of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Autoimmune responses against antigens highly expressed in type II pneumocytes may influence the severity of COVID-19 disease. The aim of this study was to investigate autoreactive T cell responses against self-antigens highly expressed in type II pneumocytes in the blood of COVID-19 patients with severe and non-severe disease. We collected blood samples of COVID-19 patients with varying degrees of disease severity and of pre-pandemic controls. T cell stimulation assays with peptide pools of type II pneumocyte antigens were performed in two independent cohorts to analyze the autoimmune T cell responses in patients with non-severe and severe COVID-19 disease. Target cell lysis assays were performed with lung cancer cell lines to determine the extent of cell killing by type II PAA-specific T cells.Results: We identified autoreactive T cell responses against four recently described self-antigens highly expressed in type II pneumocytes, known as surfactant protein A, surfactant protein B, surfactant protein C and napsin A, in the blood of COVID-19 patients. These antigens were termed type II pneumocyte-associated antigens (type II PAAs). We found that patients with non-severe COVID-19 disease showed a significantly higher frequency of type II PAA-specific autoreactive T cells in the blood when compared to severely ill patients. The presence of high frequencies of type II PAA-specific T cells in the blood of non-severe COVID-19 patients was independent of their age. We also found that napsin A-specific T cells from convalescent COVID-19 patients could kill lung cancer cells, demonstrating the functional and cytotoxic role of these T cells. Our data suggest that autoreactive type II PAA-specific T cells have a protective role in SARS-CoV-2 infections and the presence of high frequencies of these autoreactive T cells indicates effective viral control in COVID-19 patients. Type II-PAA-specific T cells may therefore promote the killing of infected type II pneumocytes and viral clearance." @default.
• W4387474477 created "2023-10-11" @default.
• W4387474477 creator A5002415432 @default.
• W4387474477 creator A5002998900 @default.
• W4387474477 creator A5004823373 @default.
• W4387474477 creator A5005687258 @default.
• W4387474477 creator A5006485099 @default.
• W4387474477 creator A5008492560 @default.
• W4387474477 creator A5013766186 @default.
• W4387474477 creator A5013777054 @default.
• W4387474477 creator A5015181430 @default.
• W4387474477 creator A5019091494 @default.
• W4387474477 creator A5024502000 @default.
• W4387474477 creator A5025951404 @default.
• W4387474477 creator A5036224456 @default.
• W4387474477 creator A5037839310 @default.
• W4387474477 creator A5038273981 @default.
• W4387474477 creator A5039973348 @default.
• W4387474477 creator A5042078063 @default.
• W4387474477 creator A5061951180 @default.
• W4387474477 creator A5062276569 @default.
• W4387474477 creator A5063392387 @default.
• W4387474477 creator A5063583813 @default.
• W4387474477 creator A5068285493 @default.
• W4387474477 creator A5072447229 @default.
• W4387474477 creator A5077178350 @default.
• W4387474477 creator A5080523158 @default.
• W4387474477 creator A5087367936 @default.
• W4387474477 creator A5087984672 @default.
• W4387474477 creator A5090698825 @default.
• W4387474477 date "2023-11-01" @default.
• W4387474477 modified "2023-10-14" @default.
• W4387474477 title "Autoreactive T cells targeting type II pneumocyte antigens in COVID-19 convalescent patients" @default.
• W4387474477 cites W1547955534 @default.
• W4387474477 cites W2008249012 @default.
• W4387474477 cites W2041711928 @default.
• W4387474477 cites W2101818249 @default.
• W4387474477 cites W2119650820 @default.
• W4387474477 cites W2324838759 @default.
• W4387474477 cites W2950891712 @default.
• W4387474477 cites W3001118548 @default.
• W4387474477 cites W3009912996 @default.
• W4387474477 cites W3014573995 @default.
• W4387474477 cites W3018949454 @default.
• W4387474477 cites W3024541652 @default.
• W4387474477 cites W3025133961 @default.
• W4387474477 cites W3037236296 @default.
• W4387474477 cites W3052573234 @default.
• W4387474477 cites W3103140952 @default.
• W4387474477 cites W3156297617 @default.
• W4387474477 cites W3161461403 @default.
• W4387474477 cites W4210642183 @default.
• W4387474477 cites W4210792795 @default.
• W4387474477 cites W4294295963 @default.
• W4387474477 doi "https://doi.org/10.1016/j.jaut.2023.103118" @default.
• W4387474477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37826919" @default.
• W4387474477 hasPublicationYear "2023" @default.
• W4387474477 type Work @default.
• W4387474477 citedByCount "0" @default.
• W4387474477 crossrefType "journal-article" @default.
• W4387474477 hasAuthorship W4387474477A5002415432 @default.
• W4387474477 hasAuthorship W4387474477A5002998900 @default.
• W4387474477 hasAuthorship W4387474477A5004823373 @default.
• W4387474477 hasAuthorship W4387474477A5005687258 @default.
• W4387474477 hasAuthorship W4387474477A5006485099 @default.
• W4387474477 hasAuthorship W4387474477A5008492560 @default.
• W4387474477 hasAuthorship W4387474477A5013766186 @default.
• W4387474477 hasAuthorship W4387474477A5013777054 @default.
• W4387474477 hasAuthorship W4387474477A5015181430 @default.
• W4387474477 hasAuthorship W4387474477A5019091494 @default.
• W4387474477 hasAuthorship W4387474477A5024502000 @default.
• W4387474477 hasAuthorship W4387474477A5025951404 @default.
• W4387474477 hasAuthorship W4387474477A5036224456 @default.
• W4387474477 hasAuthorship W4387474477A5037839310 @default.
• W4387474477 hasAuthorship W4387474477A5038273981 @default.
• W4387474477 hasAuthorship W4387474477A5039973348 @default.
• W4387474477 hasAuthorship W4387474477A5042078063 @default.
• W4387474477 hasAuthorship W4387474477A5061951180 @default.
• W4387474477 hasAuthorship W4387474477A5062276569 @default.
• W4387474477 hasAuthorship W4387474477A5063392387 @default.
• W4387474477 hasAuthorship W4387474477A5063583813 @default.
• W4387474477 hasAuthorship W4387474477A5068285493 @default.
• W4387474477 hasAuthorship W4387474477A5072447229 @default.
• W4387474477 hasAuthorship W4387474477A5077178350 @default.
• W4387474477 hasAuthorship W4387474477A5080523158 @default.
• W4387474477 hasAuthorship W4387474477A5087367936 @default.
• W4387474477 hasAuthorship W4387474477A5087984672 @default.
• W4387474477 hasAuthorship W4387474477A5090698825 @default.
• W4387474477 hasConcept C147483822 @default.
• W4387474477 hasConcept C159047783 @default.
• W4387474477 hasConcept C203014093 @default.
• W4387474477 hasConcept C2776090121 @default.
• W4387474477 hasConcept C71924100 @default.
• W4387474477 hasConcept C86803240 @default.
• W4387474477 hasConcept C8891405 @default.
• W4387474477 hasConceptScore W4387474477C147483822 @default.
• W4387474477 hasConceptScore W4387474477C159047783 @default.
• W4387474477 hasConceptScore W4387474477C203014093 @default.

• next